Zomedica Says Continuing Dialogue With Senior Regulatory Staff At NYSE American Regarding Next Steps To Regaining Compliance With Its Listing Standards
Portfolio Pulse from Benzinga Newsdesk
Zomedica is in ongoing discussions with NYSE American senior regulatory staff about regaining compliance with listing standards. Despite holding a Special Meeting of Shareholders to attempt an 80:1 share consolidation, the required 67.7% majority vote was not met. Zomedica remains listed on the NYSE American for now, following a formal notice of non-compliance received on September 13, 2023.
March 13, 2024 | 8:57 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Zomedica is actively working to regain compliance with NYSE American listing standards after failing to pass a crucial 80:1 share consolidation vote.
Zomedica's failure to pass the 80:1 share consolidation vote indicates potential challenges in regaining compliance with NYSE American listing standards. This situation could lead to negative investor sentiment and pressure on the stock price in the short term, as it raises concerns about the company's ability to maintain its listing status.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100